Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
about
Identification of unique microRNA signature associated with lupus nephritisOverview of the biology of type I interferonsInterferon-induced protein IFIT4 is associated with systemic lupus erythematosus and promotes differentiation of monocytes into dendritic cell-like cellsMolecular mechanisms of autoimmunity triggered by microbial infection.Type I interferonopathies in pediatric rheumatologyIdentification of Candidate Predictors of Lupus FlareLinking susceptibility genes and pathogenesis mechanisms using mouse models of systemic lupus erythematosusImmunomodulatory functions of type I interferonsRole of type I interferons in the activation of autoreactive B cellsType I interferon blockade in systemic lupus erythematosus: where do we stand?Intracellular nucleic acid sensors and autoimmunityUnmet medical needs in systemic lupus erythematosusCurrent perspectives on systems immunology approaches to rheumatic diseases.Applications of systems approaches in the study of rheumatic diseases.Potential serum and urine biomarkers in patients with lupus nephritis and the unsolved problemsType I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosisIRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosusConstitutive type I interferon modulates homeostatic balance through tonic signalingInterferon alpha-induced lupus: proof of principleGene-gene-sex interaction in cytokine gene polymorphisms revealed by serum interferon alpha phenotype in juvenile dermatomyositisNetwork analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosusAn interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activityHigh serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosusGenetic complementation results in augmented autoantibody responses to lupus-associated antigens.Isolation and expression profiling of genes upregulated in the peripheral blood cells of systemic lupus erythematosus patients.Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus.Gene expression and pathway analysis of immune thrombocytopenic purpura.Interferon-alpha treatment of female (NZW x BXSB)F(1) mice mimics some but not all features associated with the Yaa mutation.Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-α and TNF-α in systemic lupus erythematosus.Distinct Functions of Autoantibodies Against Interferon in Systemic Lupus Erythematosus: A Comprehensive Analysis of Anticytokine Autoantibodies in Common Rheumatic DiseasesSystems biology of lupus: mapping the impact of genomic and environmental factors on gene expression signatures, cellular signaling, metabolic pathways, hormonal and cytokine imbalance, and selecting targets for treatment.Dosage of X-linked Toll-like receptor 8 determines gender differences in the development of systemic lupus erythematosus.Association of endogenous anti-interferon-α autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus.Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus PatientsGenetic regulation of serum cytokines in systemic lupus erythematosusGenetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patientsProliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophagesInterferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study.Interferon-alpha: a therapeutic target in systemic lupus erythematosusT-helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus?
P2860
Q21136392-C622F629-C1DE-4D91-A849-4231F1797B70Q21195364-B9932639-4087-4BDF-B68A-2F0EC93AE531Q24323367-83B432C0-2494-4873-AD54-C37FAAB8EE47Q24812576-84315433-1D0F-4C59-81F9-5515D59D152AQ26748746-4F7F137A-09BE-4A8C-AB29-D2C8538EC758Q26795372-7289A124-C273-42A9-9B05-F6D33E12FE92Q26822662-6ABF699E-79B7-4CF8-AD85-C4711245E040Q26823904-44CA49A0-CDCA-4568-9BAD-820E5394F753Q26858821-C136941D-9C6A-43D2-866B-DE8DA2428992Q26865441-58C80141-BA3F-449B-9EFF-9C425FEB687AQ26997316-863470C5-2A91-442B-957C-D573A03382AEQ27005906-DA3CAC8A-9584-416A-9710-37DCF920508FQ27687400-6CBEE01F-32E9-4DEE-B4A0-D9D39FE609F9Q27692558-91A646B6-246E-4863-BCD8-B709D409A0F9Q28071798-9DC92CB9-D2EC-4D99-987B-6B439C14230CQ28251763-59396FD3-59EC-4513-8945-5284F713266EQ28253129-3306D0C8-FA2F-4A39-B43C-FB1EB92353C2Q28260631-7F784E9F-AA80-4729-8E78-156497923FF7Q28282720-E14FB705-27A1-48F4-A2EB-246D0BF10EDEQ28287170-93F2A4DA-B1A1-422E-BBDB-25E2FDFE28A4Q28301151-110EBE74-D25C-4327-B206-6B03A68E58BAQ28303311-98F5E9D5-ECCE-4FCE-9C9A-B72AEA95E4E5Q28307075-968E13EE-9D5B-496F-8917-EF2380AEA187Q30434941-A11A1928-766A-4C71-88AD-6129CEB81C22Q30817633-F1298F1A-ADBE-4581-BCEF-0BFD6C03CF59Q30873883-5AB8AB9E-6864-4F97-A92F-75A52E5B60A6Q33377373-BFEB660F-2AF8-4F9F-A80C-1284C8C3D246Q33383946-E18C48FD-09EB-40E4-B6AE-C1B1A4E86645Q33393060-8403488D-BDA2-4EE3-A56E-C7D857A872C5Q33563703-38B57382-8F50-4192-A454-3E1869E68C78Q33608479-B70942CF-A457-4465-91DF-A54D450ABEDBQ33637487-02AB8B13-B2F5-47BC-96C0-2D86CDE39F03Q33637845-122DDF97-570D-4054-BE04-7606BC2AB1E8Q33662822-BF8E3F12-015C-4BC9-9A7F-4F7228C3FE3DQ33682879-32A2405F-863B-4CD6-8478-C2EF3791B1E8Q33703923-A5342897-F411-46C9-9E8B-4ACC8883B81FQ33733803-8247D3CD-0796-4CAA-8889-32F518EFA0DEQ33743791-89C715D6-759A-42D1-8ABA-D93291C97BD2Q33744320-3718E03C-149B-40DA-8289-E00A30D9D11FQ33765598-E8C8791F-2B1A-49B2-8747-9FD906256995
P2860
Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Activation of the interferon-a ...... c features and active disease.
@en
Activation of the interferon-a ...... c features and active disease.
@nl
type
label
Activation of the interferon-a ...... c features and active disease.
@en
Activation of the interferon-a ...... c features and active disease.
@nl
prefLabel
Activation of the interferon-a ...... c features and active disease.
@en
Activation of the interferon-a ...... c features and active disease.
@nl
P2093
P356
P1476
Activation of the interferon-a ...... c features and active disease.
@en
P2093
Christina Lee
Kyriakos A Kirou
Kyriakos Louca
Margaret G E Peterson
Mary K Crow
Sandhya George
P304
P356
10.1002/ART.21031
P577
2005-05-01T00:00:00Z